Instrument Inactif

Communiqués Briacell Therapeutics Corp Toronto S.E.

Actions

CA10778Y1043

Recherche biotechnologique et médicale

Communiqués

02/06	BriaCell Therapeutics Announces Closing of Offering	AQ
01/06	BriaCell Presents Positive Clinical Data at ASCO 2026	AQ
01/06	BriaCell Therapeutics Announces Pricing of Offering	AQ
26/05	BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer	AQ
22/05	BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026	AQ
18/05	BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+	AQ
15/05	BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™	AQ
14/05	BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer	AQ
13/05	BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study	AQ
12/05	BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients	AQ
11/05	BriaCell Therapeutics : Investor Presentation (2026May11 Investor Presentation website Final)	PU
11/05	BriaCell Therapeutics : Investor Presentation (2026May11 Investor Presentation website )	PU
07/05	BriaCell Adds NYU Langone Health’s Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study	AQ
06/05	BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer	AQ
27/04	BriaCell Announces Six Clinical Data Presentations at ASCO 2026	AQ
21/04	BriaCell Therapeutics : Fact Sheet (20260421 Fact Sheet)	PU
21/04	BriaCell Therapeutics : Investor Presentation (2026Apr21 Investor Presentation)	PU
21/04	BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models	AQ
20/04	BriaCell Therapeutics : Investor Presentation (2026Apr20 Investor Presentation)	PU
20/04	BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting	AQ
31/03	BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License	AQ
18/03	BriaCell Therapeutics : to Present Positive Clinical Data for Bria-IMT(TM) and Preclinical Data for Next Generation Bria-OTS+(TM) Personalized Immunotherapy at the 2026 AACR Conference	PU
18/03	BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference	AQ
17/03	BriaCell Therapeutics : Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients	PU
10/03	BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting	AQ